Stay updated on Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.

Latest updates to the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page
- Check3 days agoChange DetectedVersion updated to v3.0.2; older v3.0.1 tag and the Back to Top element were removed.SummaryDifference0.3%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3%
- Check17 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new content related to Hemic and Lymphatic Diseases and pembrolizumab. However, many specific disease-related terms and previous location details have been removed.SummaryDifference4%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version v2.16.11 to v2.16.12.SummaryDifference0.1%
- Check39 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11, indicating a revision in the content.SummaryDifference0.1%
- Check47 days agoChange DetectedThe web page has been updated to version 2.16.10, and a previous service alert regarding planned maintenance has been removed.SummaryDifference1%
Stay in the know with updates to Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.